What Does Wall Street See for Edwards Lifesciences's Q4?
Edwards Lifesciences (NYS: EW) is expected to report Q4 earnings on Feb. 4. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Edwards Lifesciences's revenues will expand 16.0% and EPS will grow 24.2%.
The average estimate for revenue is $499.1 million. On the bottom line, the average EPS estimate is $0.77.
Revenue details
Last quarter, Edwards Lifesciences logged revenue of $448.0 million. GAAP reported sales were 8.5% higher than the prior-year quarter's $412.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at $0.58. GAAP EPS of $0.58 for Q3 were 35% higher than the prior-year quarter's $0.43 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 75.1%, 550 basis points better than the prior-year quarter. Operating margin was 21.1%, 660 basis points better than the prior-year quarter. Net margin was 15.4%, 290 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $1.89 billion. The average EPS estimate is $2.55.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 146 members out of 197 rating the stock outperform, and 51 members rating it underperform. Among 59 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Edwards Lifesciences a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is hold, with an average price target of $104.37.
Is Edwards Lifesciences the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
Add Edwards Lifesciences to My Watchlist.
The article What Does Wall Street See for Edwards Lifesciences's Q4? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
